Real‐World Use of Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing Variations
Around half of patients studied were non-persistent with any given b/tsDMARD within a year of initiating therapy. Persistence was not considerably affected by index b/tsDMARD mode of action or history of b/tsDMARD treatment. Patient characteristics associated with decreased persistence probability, including female sex and dactylitis, may help clinicians recognize patients who may benefit from additional support to improve long-term treatment outcomes.
Authors
- Jeffrey R. Curtis (ORCID: https://orcid.org/0000-0002-8907-8976)
- Jessica A. Walsh (ORCID: https://orcid.org/0000-0002-4563-0845)
- Lianne S. Gensler (ORCID: https://orcid.org/0000-0001-6314-5336)
- Sarah Welby (ORCID: https://orcid.org/0000-0003-3217-9490)
- Maureen Dubreuil (ORCID: https://orcid.org/0000-0002-6253-1515)
- Olga Pilipczuk (ORCID: https://orcid.org/0000-0001-7078-2544)
- Michael Frank Mørup (ORCID: https://orcid.org/0000-0002-1987-1223)
- V. Taieb (ORCID: https://orcid.org/0000-0003-0655-8630)
- Silky Beaty (ORCID: https://orcid.org/0000-0002-1071-802X)
- Suzanne Anjohrin
- Atul A. Deodhar (ORCID: https://orcid.org/0000-0002-2130-1246)
Institutions
- Boston University (US)
- Oregon Health & Science University (US)
- University of California, San Francisco (US)
- University of Alabama at Birmingham (US)
- VA Salt Lake City Healthcare System (US)
- UCB Pharma (France) (FR)
- Utah Department of Health (US)
- UCB Pharma (United States) (US)
- Universitetshospitalernes Center for Sundhedsfaglig Forskning (DK)
- UCB Pharma (Belgium) (BE)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1002/pds.70197
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- UCB